Granted Patent
B2
US 12,590,083 · App. 17/310,179 · Granted Mar 31, 2026
Inhibitors of spinster homolog 2 (SPNS2) for use in therapy
Inventors:
Kevin R. Lynch (Charlottesville, VA); Yugesh Kharel (Charlottesville, VA); Webster L. Santos (Blacksburg, VA); Ashley Peralta (Blacksburg, VA); Russell G. Fritzemeier (Christiansburg, VA); Daniel Foster (Blacksburg, VA)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides SPNS2 inhibitor compounds according to Formula I and their pharmaceutically acceptable salts, and/or tautomers as described in the disclosure, and the disclosure provides their pharmaceutical compositions and methods of use in therapy.
Claims (47)
1 . A compound or pharmaceutically acceptable salt thereof, wherein the compound is selected from the following table:
Com-
pound
Structure
5a
5e
5f
5g
5h
5j
51
5p
5q
5aa
13b
13c
13d
13e
13f
13g
13h
13i
13j
21c
21d
21e
21f
21g
21j
28d
28e
28f
28g
38a
38b
38c
38d
38g
38h
38i
38j
38k
38l
38n
38o
38p
2 . A pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier.
Assignments (5)
CONFIRMATORY LICENSE
Recorded Jan 9, 2023
From: UNIVERSITY OF VIRGINIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 062320/0717 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 5, 2021
From: LYNCH, KEVIN R.; KHAREL, YUGESH
To: UNIVERSITY OF VIRGINIA
Reel/Frame 057085/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 5, 2021
From: UNIVERSITY OF VIRGINIA
To: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
Reel/Frame 057085/0468 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 5, 2021
From: SANTOS, WEBSTER L.; PERALTA, ASHLEY N.; FRITZEMEIER, RUSSELL G.; FOSTER, DANIEL
To: VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY
Reel/Frame 057085/0495 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 5, 2021
From: VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY
To: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.
Reel/Frame 057085/0499 →
Continuity (2)
Provisional Application
62797054
· Jan 25, 2019
References Cited (45)
US 9688668B2
· Santos
· 2017
[cited by examiner]
US 20090197897A1
· Bugada et al.
· 2009
[cited by applicant]
US 20140057895A1
· Mizuno
· 2014
[cited by examiner]
US 20230331683A1
· Lynch et al.
· 2023
[cited by applicant]
US 20230373937A1
· Lynch et al.
· 2023
[cited by applicant]
EP 3275440
· 2018
[cited by applicant]
WO 03062252
· 2003
[cited by applicant]
WO WO2005044797A1
· 2005
[cited by examiner]
WO WO2006123257A2
· 2006
[cited by examiner]
WO WO2007039781A2
· 2007
[cited by applicant]
WO 2008064320
· 2008
[cited by applicant]
WO WO2013119946A1
· 2013
[cited by examiner]
WO 2016054261
· 2016
[cited by applicant]
WO 2019018795
· 2019
[cited by applicant]
WO WO2020154431A1
· 2020
[cited by applicant]
WO 2020219792
· 2020
[cited by applicant]
WO 2020227101
· 2020
[cited by applicant]
WO 2022056042
· 2022
[cited by applicant]
WO 2022056045
· 2022
[cited by applicant]
Patwardhan et al. Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors: discovery of SphK1- and SphK2-selective inhibitors. J Med Chem. Feb. 26, 2015;58(4):1879-1…
[cited by examiner]
Tsai HC, Han MH. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation. Drugs. Jul. 2016;76(11):1067-79. doi: 10.1007/s40265-016-0603-2. PMID: 27318702. (Year: 201…
[cited by examiner]
“International Application Serial No. PCT/US2020/014651, International Search Report mailed Jun. 29, 2020”, 6 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2020/014651, Invitation to Pay Additional Fees and Partial Search Report mailed Apr. 28, 2020”, 19 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2020/014651, Written Opinion mailed Jun. 29, 2020”, 12 pgs.
[cited by applicant]
Packiarajan, Mathivanan, et al., “Azetidinyl oxadiazoles as potent mGluR5 positive allosteric modulators”, Bioorganic & Medicinal Chemistry Letters, vol. 22, No. 20, (Aug. 25, 2012), 6469-6474.
[cited by applicant]
“International Application Serial No. PCT/US2020/014651, International Preliminary Report on Patentability mailed Aug. 5, 2021”, 15 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2021/049531, International Search Report mailed Jan. 4, 2022”, 9 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2021/049531, Written Opinion mailed Jan. 4, 2022”, 10 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2021/049534, International Search Report mailed Jan. 28, 2022”, 8 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2021/049534, Written Opinion mailed Jan. 28, 2022”, 9 pgs.
[cited by applicant]
“European Application Serial No. 20709362.6, Response to Communication Pursuant to Rules 161 and 162 EPC filed Feb. 15, 2022”, 47 pgs.
[cited by applicant]
Congdon, Molly D, “Structure-Activity Relationship Studies and Molecular Modeling of Naphthalene-Based Sphingosine Kinase 2 Inhibitors”, ACS Medicinal Chemistry Letters, vol. 7, No. 3, XP055285993, (Mar. 10, 2016), 229-…
[cited by applicant]
Kharel, Yugesh, “Sphingosine kinase type 2 inhibition elevates circulating sphingosine 1-phosphate”, Biochemical Journal, 447, (Oct. 1, 2012), 149-157.
[cited by applicant]
“U.S. Appl. No. 18/044,686, Preliminary Amendment filed Mar. 9, 2023”, 19 pgs.
[cited by applicant]
“U.S. Appl. No. 18/044,688, Preliminary Amendment filed Mar. 9, 2023”, 14 pgs.
[cited by applicant]
“European Application Serial No. 21786692.0, Response filed Oct. 26, 2023 to Communication pursuant to Rules 161(1) and 162 EPC mailed Apr. 18, 2023”, 10 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2021/049531, International Preliminary Report on Patentability mailed Mar. 23, 2023”, 12 pgs.
[cited by applicant]
“International Application Serial No. PCT/US2021/049534, International Preliminary Report on Patentability mailed Mar. 23, 2023”, 11 pgs.
[cited by applicant]
“U.S. Appl. No. 18/044,686, Restriction Requirement mailed Jul. 17, 2025”, 6 pgs.
[cited by applicant]
“U.S. Appl. No. 18/044,688, Restriction Requirement mailed Jul. 23, 2025”, 10 pgs.
[cited by applicant]
“U.S. Appl. No. 18/044,686, Response filed Sep. 17, 2025 to Restriction Requirement mailed Jul. 17, 2025”, 19 pgs.
[cited by applicant]
“U.S. Appl. No. 18/044,688, Response filed Sep. 23, 2025 to Restriction Requirement mailed Jul. 23, 2025”, 15 pgs.
[cited by applicant]
“U.S. Appl. No. 18/044,688, Non Final Office Action mailed Oct. 17, 2025”, 18 pgs.
[cited by applicant]
“Chemical Abstract Registry No. 1906742-77-5, indexed in the Registry File on STN CAS”, (May 9, 2016), 4 pgs.
[cited by applicant]